Täysin automatisoitujen digitaalisten vs. valmentajapohjaisten diabeteksen ehkäisyohjelmien tehokkuus ja kustannustehokkuus
The purpose of this research study is to compare the effectiveness of a fully automated digital diabetes prevention program to standard of care human coach-based diabetes prevention programs for promoting clinically meaningful lifestyle changes to reduce the risk of type 2 diabetes in adults with prediabetes.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
After being informed about the study and potential risk, all participants giving written informed consent will undergo screening to determine eligibility for study entry. At baseline visit (month 0). Participants who meet the eligibility requirements will be randomly assigned in 1:1 ratio to human coach-based diabetes prevention program or digital diabetes prevention program. An equal number of participants will be randomly assigned to both groups (like flipping a coin).
If participants are randomly assigned to receive the human coach-based diabetes prevention program, the participants will be referred to a local Diabetes Prevention Program close to the participants' area. The Diabetes Prevention Program consists of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
If participants are randomly assigned to receive the digital Diabetes Prevention Program, the participants will receive the Sweetch Digital Health Kit (Sweetch Health, Ltd.) in the mail within approximately 8-12 days of the participants' first study visit. The Sweetch digital health kit consists of a smartphone app and a digital body weight scale that is connected via Bluetooth to the app. The phone app also consists of brief Centers for Disease Control and Prevention (CDC) lessons on type 2 diabetes prevention, which participants will be encouraged to complete.
There will be a total of 3 study visits (baseline, 6 months, and 12 months), each visit includes fingerstick hemoglobin A1C measurement, weight measurement, and completion of several questionnaires. Height will be measured at the first visit. Throughout the 12-month study, participants will be asked to wear a device on the participants' wrist to measure physical activity for 7 consecutive days following the first visit and once every month thereafter.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21287
- Johns Hopkins Hospital
-
-
Pennsylvania
-
Reading, Pennsylvania, Yhdysvallat, 19611
- Reading Hospital - Tower Health
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Provision of signed and dated informed consent form.
-
Stated willingness to comply with all study procedures and availability for the duration of the study.
-
Laboratory evidence of prediabetes, defined as any of the following lab results, in the past year:
- Hemoglobin A1C 5.7% to 6.4%
- Fasting glucose 100-125 mg/dL
- Plasma glucose of 140-199 mg/dL measured 2 hours after a 75 gm glucose load
-
Body mass index (BMI) ≥25 kg/m2 (or≥23 kg/m2 for Asians).
-
Proficiency in reading English.
-
Smartphone user (Android Operating System (OS) 9.0 or iOS 13.3 or newer).
-
Plans to reside in recruitment area for the next 12 months (participant's zip code of residence is within ~45 miles of the study recruitment site.
Exclusion Criteria:
- Medical conditions that prevent adoption of moderate physical activity (per primary care clinician).
- Aortic stenosis.
- Unstable cardiac disease (myocardial infarction, heart failure, or stroke in previous 6 months, currently participating in cardiac rehabilitation).
- Has a pacemaker, implantable cardioverter-defibrillator (ICD), or other implanted electronic device.
- Use of any glucose-lowering medications, weight loss medications, or any systemic glucocorticoids within the previous 3 months.
- Active malignancy of any type or diagnosed with or treated for cancer within the past 2 years. Individuals with basal and squamous cell carcinoma of the skin that has been successfully treated will be allowed to participate.
- Diagnosis of diabetes mellitus.
- Pregnancy or planned pregnancy in the next 12 months.
- Anemia.
- Receiving treatment for iron-deficiency anemia, vitamin B12 deficiency, or folate d efficiency.
- Hemoglobinopathy (HbS or HbC disease).
- Blood transfusion in previous 4 months.
- On dialysis or active organ transplant list.
- Treated with erythropoietin.
- Major psychiatric disorder (schizophrenia) or use of antipsychotic medications within the past 1 year.
- Dementia or Alzheimer's disease.
- Diagnosed with an eating disorder (anorexia nervosa, avoidant/restrictive food intake disorder, binge eating disorder, bulimia nervosa, Pica, rumination disorder, other specified or unspecified feeding or eating disorder)
- Diagnosed or self-reported alcohol or substance abuse.
- Known allergy to steel.
- Participation in another clinical trial related to lifestyle management or diabetes prevention.
- Currently attending or attended a diabetes prevention program in the previous 2 years.
- Unwilling to accept random assignments.
- Had bariatric surgery within the 12 months prior randomization or is planning to undergo bariatric surgery during the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Fully-Automated Digital Diabetes Prevention Program
Participants will receive Sweetch Digital Diabetes Prevention Program consists of a smartphone app and bluetooth-enabled digital body weight scale that syncs with the app. |
The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes. The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc. |
|
Active Comparator: Human Coach-Based Diabetes Prevention Program
Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach. |
The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Achievement of CDC's Benchmark for Type 2 Diabetes Risk Reduction as a Binary Outcome (Yes/no)
Aikaikkuna: 12 months
|
The primary outcome was the CDC-defined diabetes risk reduction benchmark at 12 months (based on the 2021 standards), defined as at least one of the following:
|
12 months
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Absolute Weight Change
Aikaikkuna: At 12 months
|
Absolute weight change (kilograms) from baseline to 12 months |
At 12 months
|
|
Cost-effectiveness as Assessed by the Markov Model
Aikaikkuna: 12 months
|
The investigators will compare the cost-effectiveness of the two interventions based on lifetime horizon by constructing a Markov model with model parameters populated from the trial results as well as other published literature. The model will estimate the incremental cost-effectiveness ratio between the two interventions. |
12 months
|
|
Change in Hemoglobin A1C
Aikaikkuna: At 12 months
|
Change in HbA1C (percentage points) from baseline to 12 months (among participants with baseline HbA1C of 5.7% - 6.4% who completed the 12-month study visit). |
At 12 months
|
|
Percentage Change in Weight
Aikaikkuna: At 12 months
|
Percentage change in weight from baseline to 12 months |
At 12 months
|
|
Mean Weekly Moderate-to-vigorous Physical Activity (MVPA)
Aikaikkuna: At 12 months
|
Average minutes/week of physical activity assessed using blinded Actigraphy (monthly serial consecutive 7-days wear period). If the participant did not wear their monitor for at least 5 of their 7 assigned days, they were considered noncompliant. In this case, the participant was assigned 0 minutes for physical activity for that week.To obtain the average MVPA minutes per week across the study period, the total MVPA minutes per week from all valid wear periods were summed and divided by the number of available wear periods (maximum of 11 post-baseline visits). Specifically, activity intensity was classified as MVPA if the vector magnitude of accelerometer counts per minute was equal to or greater than 3941 (Montoye's cut point). |
At 12 months
|
|
Incidence of Diabetes-range A1C
Aikaikkuna: At either 6 or 12 months
|
Number of individuals who had an AIC in the diabetes range (A1C ≥6.5%) at the 6-month or 12-month timepoint. |
At either 6 or 12 months
|
|
Acceptability as Assessed by the Diabetes Prevention Program Acceptability Scale (DPPAS)
Aikaikkuna: 12 months
|
Acceptability of the assigned intervention was assessed at 12 months using the Diabetes Prevention Program Acceptability Scale (DPPAS), Score range from 1 to 5; higher scores indicate greater acceptability (better outcome). |
12 months
|
|
Correlation Between Self-reported and Measured Physical Activity
Aikaikkuna: 6 months and 12 months
|
To evaluate the correlation between self-reported PA data collected using different methods:
|
6 months and 12 months
|
|
Program Initiation Rate
Aikaikkuna: At 12 months
|
Program initiators were defined as participants who attended at least one in-person session (Human-DPP) or registered and used the Sweetch app (AI-DPP). |
At 12 months
|
|
Program Completion Rate
Aikaikkuna: At 12 months
|
Program completers attended ≥8 sessions in months 1-6 and spanned ≥9 months (Human-DPP), or engaged with the app for ≥8 weeks during months 1-6 with a span of ≥9 months between initiation and last engagement (AI-DPP). |
At 12 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Tutkijat
Tutkijat
- Päätutkija: Nestoras Mathioudakis, MD MHS, Johns Hopkins University
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Abusamaan MS, Ballreich J, Dobs A, Kane B, Maruthur N, McGready J, Riekert K, Wanigatunga AA, Alderfer M, Alver D, Lalani B, Ringham B, Vandi F, Zade D, Mathioudakis NN. Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial. Trials. 2024 May 16;25(1):325. doi: 10.1186/s13063-024-08177-8.
- Lalani B, Siew G, Valdez Y, Shehadeh A, Zade D, Riekert K, Mathioudakis N; AI-DPP Study Group. User Engagement and Feature Preferences in an AI-Powered mHealth Intervention for Diabetes Prevention: Secondary Analysis of a Randomized Controlled Trial. JMIR Mhealth Uhealth. 2026 Sep 2;14:e92981. doi: 10.2196/92981.
- Mathioudakis N, Lalani B, Abusamaan MS, Alderfer M, Alver D, Dobs A, Kane B, McGready J, Riekert K, Ringham B, Shehadeh A, Vandi F, Wanigatunga AA, Zade D, Maruthur NM; AI-DPP Study Group. An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial. JAMA. 2025 Dec 16;334(23):2079-2089. doi: 10.1001/jama.2025.19563.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Todellinen)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Endokriinisen järjestelmän sairaudet
- Ravitsemushäiriöt
- Metaboliset sairaudet
- Yliravitsemus
- Kehon painon muutokset
- Glukoosiaineenvaihduntahäiriöt
- Diabetes mellitus
- Patologiset tilat, merkit ja oireet
- Käyttäytyminen
- Ravitsemukselliset ja aineenvaihduntataudit
- Merkit ja oireet
- Ylipainoinen
- Lihavuus
- Painonpudotus
- Kehon paino
- Hyperglykemia
- Prediabeettinen tila
- Glukoosi-intoleranssi
- Motorinen toiminta
- Istuva käyttäytyminen
- Riskinvähentämiskäyttäytyminen
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- IRB00265873
- 1R01DK125780-01 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The Data Coordinating Center (Johns Hopkins University) will prepare a de-identified database that is consistent with HIPAA requirements. The de-identified database will include all study research data and will be stored in a repository at Johns Hopkins University (archive.data.jhu.edu) at a time that will coincide with the online publication of the study primary endpoint paper. The repository will contain documentation designed to facilitate use of the database. The documentation prepared for the repository will include a list and timetable for secondary and exploratory papers planned by the study investigators. Access to the database will be restricted to qualified users. Qualified users will include those investigators who submit valid pre-specified hypotheses and certify that they will not use the data for commercial purposes.
IPD-jaon aikakehys
The study protocol will be submitted for publication within 1 year of the start of enrollment.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .